TDC
IRON icon

Thompson Davis & Co’s Disc Medicine IRON Stock Holding History

Thompson Davis & Co’s Portfolio IRON Stock Details IRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-6,800
Closed -$302K – 126
2023
Q2 		$302K Buy
+6,800
New +$241K 0.34% 56

Other funds holding IRON

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Thompson Davis & Co's IRON Position: Q3 2023 in Review

Thompson Davis & Co sold out of Disc Medicine (IRON) in Q3 2023, closing a stake of 6,800 shares — an estimated $302K sold.

Thompson Davis & Co first reported a position in IRON in Q2 2023 and held it in 1 quarter. The position peaked at $302K in Q2 2023. 91 funds tracked by Wall St. Rank hold IRON as of Q3 2023.

  • Thompson Davis & Co reported no remaining Disc Medicine position as of Q3 2023 after selling out during the quarter.
  • Thompson Davis & Co sold 6,800 Disc Medicine shares in Q3 2023, an estimated $302K.
  • Thompson Davis & Co first reported a position in Disc Medicine in Q2 2023 and held it in 1 quarter.
  • Thompson Davis & Co's Disc Medicine position peaked at $302K in Q2 2023.
  • 91 funds tracked by Wall St. Rank held Disc Medicine as of Q3 2023.

Based on Thompson Davis & Co's 13F filing for Q3 2023, filed 9 Nov 2023.